Endogenous myostatin and activin antagonist. Studied for muscle hypertrophy, fertility, and metabolic effects. Significantly increases lean body mass in animal models. Limited human pharmacokinetic data.
Not well-characterized for exogenous administration; endogenous forms have local tissue activity
SKUs
1
Evidence
Emerging
Follistatin-344 is a form of follistatin, a naturally occurring protein that binds to and inhibits myostatin and other members of the TGF-beta protein family. By blocking myostatin — a key regulator that limits muscle growth — follistatin has been studied as a way to increase muscle mass. Research includes gene therapy approaches and direct protein delivery, but the research is primarily preclinical.
Muscle Mass Research
Follistatin's most studied application is inhibiting myostatin to allow greater muscle growth. In animal studies, overexpression of follistatin or myostatin knockout produces dramatically increased muscle mass. Gene therapy trials delivering follistatin to muscles in boys with Duchenne muscular dystrophy have been conducted.
Muscular Dystrophy Research
Clinical gene therapy trials have delivered follistatin via adeno-associated virus (AAV) directly into muscle of patients with Duchenne muscular dystrophy and sporadic inclusion body myositis. Early results showed it was safe and produced some changes in muscle histology, though functional benefit was modest in early phases.
Body Composition Research
Beyond disease contexts, the myostatin inhibition pathway has attracted research interest for general muscle mass enhancement, particularly in sarcopenia (age-related muscle loss). Direct peptide delivery of follistatin has been studied in rodent models.
Animal studies demonstrate dramatic muscle mass increases with follistatin overexpression or myostatin inhibition.
Functional benefits in human trials have been modest in early phases.
Direct protein delivery (as opposed to gene therapy) has limited human data.
The highly dramatic muscle gains seen in animal studies have not been replicated in human gene therapy trials, which showed more modest effects. Direct protein delivery of follistatin (as opposed to gene therapy) has a very limited human evidence base. Follistatin also inhibits activin and other proteins beyond myostatin, which means its effects extend to reproduction, bone metabolism, and other systems — raising considerations about off-target effects with broad inhibition.
Myostatin is a protein that acts like a governor on muscle growth — it signals muscle tissue to limit how large it can become. This is a natural regulatory mechanism that prevents excessive muscle growth. Follistatin is a protein that binds to myostatin (and similar proteins) and neutralizes it, essentially releasing the brake. With myostatin blocked, muscles can grow larger in response to the same exercise or growth signals. The idea is appealing for conditions where muscles are wasting away and more mass would be beneficial. The challenge is that follistatin does not just block myostatin — it also affects other related proteins involved in reproduction and other biological systems, which complicates its use as a targeted therapy.
AAV gene therapy trials showed favorable safety for muscle-targeted follistatin delivery. Direct injectable follistatin protein delivery as a research compound lacks an established safety profile in humans. Because follistatin inhibits activin and other TGF-beta family members beyond myostatin, broad inhibition could affect reproductive hormones, bone density, and other systems. It is not FDA-approved for body composition purposes. Research use carries significant unknowns.
Emerging
This compound is in early-stage research. Evidence is limited to small studies or in vitro data.
Published Research Ranges
Research phase only; gene therapy vectors more studied; injectable pharmacology limited data
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Follistatin Is an In Vivo Inhibitor of Myostatin: Evidence from Gene Therapy
Journal of Clinical Investigation • 2000
• DOI: 10.1172/JCI9602
Targeting Cellular Senescence in Aging and Age-Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies
Physiological Changes and Pathological Pain Associated with Sedentary Lifestyle-Induced Body Systems Fat Accumulation and Their Modulation by Physical Exercise
Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.